Abnormal Uterine Bleeding Management

Not Applicable

Recruiting

• Conditions: Health Condition 1: N939- Abnormal uterine and vaginal bleeding, unspecified

• Registration Number: CTRI/2021/12/038921
• Lead Sponsor: Magnet Labs under Mankind Pharma

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2023-06-26

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Women of reproductive age group 18-45 years.

2. Excessive bleeding during menstruation (menstrual blood loss > 80 ml in 1-7 days) or having Pictorial blood loss assessment chart (PBLAC) score more than 100 points for 2 consecutive cycles.

3.Prolonged menstrual bleeding (With the duration of bleeding >7 days) Inter menstrual bleeding

4.Frequent menstrual cycle (interval < 21 days)

5.Patients who are willing to go for relevant investigation

6.Normal gynaecological examination and PAP smear

Exclusion Criteria

•Patients with any diagnosed uterine organic pathology like Adenomyosis, and chronic tubo ovarian mass.

•Submucosal or intramural fibroids, or subcervical fibroids greater than 3cm.

•Patients with systemic diseases like hypertension, diabetic mellitus, congestive cardiac failure etc.

•Patients with coagulopathy, liver and thyroid dysfunction etc.

•Patient with malignancy or undiagnosed neoplasm.

•Patients with history of recent abortion.

•Patients with active genital tuberculosis.

•Bleeding from the polyps and erosion.

•IUCD in utero, pelvic endometriosis.

•Hb < 8 gm/dl

Study & Design

• Study Type: Interventional
• Study Design: Not specified